Abbott Laboratories ABT shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of ...

Abbott is trading at a forward 12-month price-to-sales (P/S) multiple of 4.4X, a 22% discount to the Zacks Medical Products industry average of 5.6X. This valuation is below Abbott's five-year median ...

Abbott Laboratories engages in the discovery ... Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...

Abbott Labs is the company behind consumer ... and have the capacity and scale to produce a diverse portfolio of medical products across multiple clinical areas in need. From a business standpoint ...

The stock currently has a Zacks Rank #2 (Buy). To break things down more, Abbott belongs to the Medical - Products industry, a group that includes 82 individual companies and currently sits at #87 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Like all its peers, Abbott Laboratories ABT faced the industrywide challenges of margin pressure through 2024, stemming from growing inflation, labor shortages and supply chain disruptions, which ...